Latest news with #CTTPharma
Associated Press
10-03-2025
- Business
- Associated Press
CTT Pharma Uplists to the OTCQB Today
TAMPA, FL / ACCESS Newswire / March 9, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has entered the OTCQB Market today under the ticker symbol 'CTTH'. CTT Pharma's CEO will issue a news release to shareholders this Wednesday March 12, 2025. About CTT Pharmaceuticals Holdings, Inc. CTT has patented technology in the United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and delivering drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips dissolve quickly, deliver low dose options and offer better bioavailability.
Associated Press
05-03-2025
- Business
- Associated Press
CTT Pharmaceuticals Holdings, Inc. Announces Uplisting to OTCQB Market Trading
TAMPA, FL / ACCESS Newswire / March 5, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the OTC Markets Group has approved the trading of its common shares on the OTCQB Market. The company's common shares will trade on the OTCQB under the symbol 'CTTH' as of the opening of the market on March 10, 2025. Uplisting to the OTCQB should provide CTT with greater liquidity and a more seamless trading experience for U.S. shareholders. The OTCQB is a premier marketplace for Pharmaceutical companies in early stage that are moving towards development of new technology. Companies listed on the OTCQB are current in their reporting and undergo yearly PCAOB Audits. CTT will make a formal announcement on March 10, 2025 announcing the uplisting to the OTCQB investor community. The CEO of CTT Pharma will issue a news release to shareholders on March 12, 2025. CTT Pharma - 813-606-0060 SOURCE: CTT Pharmaceutical Holdings, Inc.
Associated Press
12-02-2025
- Business
- Associated Press
CTT Pharma Gives Update On NSF Grant
TAMPA, FL / ACCESS Newswire / February 12, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal to the National Science Foundation(NSF) for our patented fast dissolving nicotine strips. The NSF grant program is highly competitive as it receives over 12,000 applicants annually from companies that have innovations that could help society. CTT successfully made it past the first round process and is among a few thousand remaining applicants. These remaining applicants have several deadlines over the course of the year to file a full proposal into the grant program. CTT is anticipating an answer in this program in late April. Acceptance into this program would give government backing to CTT Pharma and would allow for extensive research and testing to help lead to development of our technology. The World Health Organization states, 'The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke.' Furthermore, the CDC says, 'Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly 1 in 5 deaths. The CEO of CTT Pharma, Ryan Khouri stated, 'To make it past the first round of applicants is a huge accomplishment by itself and shows that the NSF sees potential value for our technology within the tobacco industry. Currently there are no fast dissolving, low dose nicotine strips on the market, as most oral products stay in the mouth for an excessive amount of time. CTT also brought someone onto our team to help with this NSF Grant as they have a tremendous amount of experience with the NSF.' CTT Pharma - 813-606-0060 SOURCE: CTT Pharmaceutical Holdings, Inc.
Associated Press
30-01-2025
- Business
- Associated Press
CTT Pharma Submits Proposal for NIH Grant
TAMPA, FL / ACCESS Newswire / January 30, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) has submitted a grant to the National Institutes of Health (NIH) that will aid in further research and commercialization. This grant is being submitted in addition to the Johns Hopkins University grant for clinical trials and this opportunity was suggested to CTT as a grant that would allow for further research and testing. The CEO of CTT Pharma Ryan Khouri stated, 'Approval of this grant will allow for further research that ultimately would lead to commercialization of our dissolvable nicotine strips'. This grant opportunity was brought to the attention of Mr. Khouri after he attended and presented at the FDA/NIH hearing for Advancing Smoking Cessation Technology. Mr. Khouri stated that CTT Pharma's partnership with Johns Hopkins University is a main priority to fund and develop CTT's technology as a smoking cessation product, however, additional funding and relationships that can be established with the NIH to help achieve that goal are being pursued. Mr. Khouri looks forward to working with the NIH and FDA in the future and believes CTT can develop products that effectively increase smoking cessation with the resultant reduction of the risk of heart disease, stroke, and various cancers. CTT anticipates a decision made by the NIH in April 2025 and will inform shareholders accordingly. About CTT Pharmaceuticals Holdings, Inc. CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
